

References

I-212

1. Hayes, Inc. Hayes Prognosis Overview. Spravato (Esketamine) for treatment resistant depression. Landsdale, PA: Hayes, Inc.; March 2019.
2. Morrison R, Fedgchin m, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: A randomized, double-blind, placebo-controlled study. 2018;235:1107-1119.
3. Daly E, Singh J, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment resistant depression: A randomized clinical trial. *JAMA Psychiatry*. 2018;75(2):139-148.
4. Spravato™ (esketamine) nasal spray [package insert]. Titusville, NJ. Janssen Pharmaceuticals, Inc. 02/2020.
5. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
6. Canuso C, Singh J, Fedgchin M et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*. ;175:620-630.
7. Targum S, Daly E, Fedgchin M, Cooper K, & Singh J. Comparability of blinded remote and site based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. *J Psych Res*. 2019;111:68-73.
8. Hayes, Inc. Hayes Medical Technology Directory Report. Esketamine (Spravato) for Treatment Resistant Major Depressive Disorder Lansdale, PA: *Hayes, Inc.*; November, 2019. Accessed May 7, 2020.
9. Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. *JAMA Psychiatry*. 2019;76(9):893-903.

10. Wajs E, Aluisio L, Holder R, et.al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a Phase 3, open-label study (SUSTAIN-2). *J Clin Psychiatry*. 2020;81(3)
11. Clinical Pharmacology™ Compendium. 2020. Tampa FL: Gold Standard, Inc. Esketamine.
12. Micromedex DrugDex Compendium®. 2020. Esketamine.
13. Kryst J, Kawalec P, Pilc A. et.al. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. *Expert Opinion on Pharmacotherapy*, 2020;21(1), 9-20.
14. Fu D J, Ionescu D, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). *J Clin Psychiatry*. 2020;81(3):19m13191.